Does Sandostatin Cause Gallstones with Long-Term Use?
Yes, long-term use of Sandostatin (octreotide) is associated with an increased risk of gallstones, or cholelithiasis. This occurs because the drug inhibits gallbladder motility and reduces bile acid secretion, leading to bile stasis and stone formation. Studies show this risk rises with duration and dose: up to 20-30% of patients on continuous subcutaneous infusions for over 12 months develop gallstones, compared to under 5% in short-term users.[1][2]
How Common Is This in Clinical Data?
In trials for acromegaly and carcinoid syndrome, gallstone incidence reached 52% after 3+ years of Sandostatin LAR (long-acting release) at 20-30 mg monthly. Most cases are asymptomatic, but 10-20% may cause complications like cholecystitis or require surgery. Risk is dose-dependent and higher with depot formulations.[3][4]
Why Does It Happen—What's the Mechanism?
Octreotide suppresses cholecystokinin release, impairing gallbladder contraction. It also lowers gallbladder emptying rates from normal 70-80% post-meal to under 20%, promoting cholesterol supersaturation in bile. This effect is reversible upon discontinuation, but stones may persist.[1][5]
What Should Patients Watch For?
Symptoms include right upper abdominal pain, nausea, bloating, or jaundice, often after fatty meals. Routine ultrasound monitoring is recommended for long-term users (e.g., every 6-12 months). Prophylactic ursodiol can reduce risk by 70-90% in high-risk cases.[2][6]
How Does Risk Compare to Alternatives Like Lanreotide?
Lanreotide (Somatuline), another somatostatin analog, carries a similar 20-40% gallstone risk with long-term use, though some head-to-head data suggest slightly lower incidence. Both require similar monitoring; switching doesn't eliminate risk.[4][7]
Management and Prevention Options
Asymptomatic stones often need no treatment. Symptomatic cases may require cholecystectomy (80% laparoscopic success). Prevention includes lowest effective dose, intermittent dosing if possible, and bile acid therapy. FDA labeling warns of this risk for all octreotide products.[3][8]
[1]: FDA Sandostatin LAR Label
[2]: NEJM Study on Octreotide and Gallstones
[3]: DrugPatentWatch.com - Sandostatin Patents and Labels
[4]: Pituitary Journal Review - Somatostatin Analogs
[5]: Gastroenterology - Octreotide Gallbladder Effects
[6]: Clinical Guidelines - Acromegaly Management
[7]: Lanreotide vs. Octreotide Meta-Analysis
[8]: Sandostatin Package Insert